Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Technology

Clinical Trials

Artificial Intelligence

Pharmaceutical

Biotechnology

Exscientia plc

More Like This

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Exscientia to Present at Upcoming Investor Conferences in June

Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference